Pranlukast is a leukotriene receptor antagonist for the treatment of allergic rhinitis and asthma symptoms. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
- Mechanism
- Curator reviewed
Pranlukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Pranlukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
- Primary indication
- Used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.Curator reviewed · 3 structured indications
- Formula / weight
- C27H23N5O4 · 481.512 g/mol (avg)
- Code names
- CCN-00401 · ONO-1078 · ONO-RS 411 · RS-411 · SB-205312
Resolves to
NBQKINXMPLXUET-UHFFFAOYSA-NSMILESO=C(NC1=C2OC(=CC(=O)C2=CC=C1)C1=NNN=N1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Pranlukast, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account